Zogenix racing to FDA with abuse-resistant Zohydro; Emerald raises cash, launches virtual lab;

@FierceBiotech:  | Follow @FierceBiotech

@JohnCFierce: Interesting Porges note spotlights $GILD's 67% success rate in deals--95% success rate by $$$--since 2000. No doubt Sovaldi helped... | Follow @JohnCFierce

@DamianFierce: Oct. 2013: Seragon raises $30M Series A. July 2014: $RHHBY buys it for up to $1.7B. News | Follow @DamianFierce

@EmilyMFierce: Chikungunya: Tracing a Virus's Past to Predict its Future. Story from The Scientist | Follow @EmilyMFierce

Under assault by critics and facing serious competition from development rivals, San Diego-based Zogenix ($ZGNX) says it's racing ahead on the development of an abuse-deterrent version of the pain killer Zohydro. The biotech now says it can file a supplemental NDA by October, accelerating its timeline for returning to the agency. Release

The lab research company Emerald Therapeutics has raised new funding, bringing its total to $13.5 million. Emerald also has its first product: the Emerald Cloud Laboratory. The ECL is a "state-of-the-art life sciences laboratory that scientists can remotely access via the Internet." Release

> New York-based Retrophin has added $45 million in debt. Release

The heart disease specialist Cardio3 BioSciences has raised  €25 million ($34 million). Release

> Novato, CA-based Raptor Pharmaceutical struck agreements for $70 million in funding from HealthCare Royalty Partners and its affiliates in a private placement. Release

Medical Device News

@FierceMedDev: Muscle cell-powered 'bio-bot' could carry drugs. Story | Follow @FierceMedDev

@StacyALawrence: In obesity device race, ReShape lines up with FDA. Article | Follow @StacyALawrence

@VarunSaxena2: AHRQ report highlights government concern over chronic wound care, home healthcare. Story | Follow @VarunSaxena2

@MichaelGFierce: Nanoparticles designed to prevent cancer, aid bones. More from Laboratory Equipment | Follow @MichaelGFierce

@EmilyWFierce: Which med tech CEOs took home the biggest paychecks in 2013? Find out here: Feature | Follow @EmilyWFierce

> Intuitive Surgical kicks off da Vinci sales in Japan. Article

> Med techs Cerus, Amedica score $56M in debt. Story

> Canada to implement UDI based solely on international guidelines. Report

Pharma News

@FiercePharma: Once again, top-read on FP yesterday: Sex, bribes and videotape: Clandestine video of $GSK exec adds to China scandal. Article | Follow @FiercePharma

@TracyStaton: ICYMI: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: ICYMI: This Indian pharma exec understands how to attain quality production & that many of his compatriots do not. More | Follow @EricPFierce

@CarlyHFierce: In case anybody missed this one, here are the top 5 vaccines by 2020. Feature | Follow @CarlyHFierce

> Not for sale, says new Actavis CEO. We're buying instead. Story

> Takeda COO Weber's reset plans include acquisitions, market expansion. More

> France aims to save big bucks by subbing unapproved Avastin for eye drug Lucentis. Article

Drug Delivery News

> Muscle cell-powered 'bio-bot' could carry drugs. Story

> Researchers aim to sneak antibiotics into bacteria via naturally occurring molecule. Article

> BMS recalls injectable warfarin, oral formulation unaffected. More

> MicroRNA delivery specialist Microlin Bio nears $30 million IPO. Article

> Targeted nanoparticles home in on myeloma and strengthen bones. Story

Diagnostics News

> Roche and New Zealand university launch lab team for Dx development and training. Article

> GE Healthcare's Alzheimer's imaging agent gains backing of key EU agency committee. News

> Report: Abbott is cutting diagnostics division jobs. More

> NIH keeps Corgenix Ebola Dx project running with new funding. Article

> Abcodia will license access to serum biobank for cardiovascular disease biomarker work. Story

Pharma Marketing News

> Facing threats from Purdue, Teva and Pfizer, Zogenix puts Zohydro follow-up into high gear. More

> The FDA should step up its own social-media action, NEJM researchers say. Report

> Study: Med students cozy with industry reps more likely to dole out branded drugs. More

> With a new IPF drug on its way, Boehringer backs a Discovery documentary on the lung disease. Story

> Now that it's FDA-approved, MannKind has to actually sell its inhaled insulin Afrezza. Article

> J&J, Pfizer in tug-of-war over ads for Infants' Advil. News